Factors Affecting Pediatric Dyslipidemia Screening and Treatment

Clinical Pediatrics
Lisa HerringtonElizabeth Hisle-Gorman

Abstract

Identification and management of dyslipidemia in childhood can reduce future cardiovascular risk. We performed a retrospective cohort study of children ages 2 to 18 years during 2009 to 2013 to evaluate factors that affect screening and treatment of pediatric dyslipidemia related to 2011 National Heart, Lung, and Blood Institute (NHLBI) guidelines. Logistic regression analysis determined the impact of NHLBI-identified factors on odds of being screened, elevated low-density lipoprotein cholesterol (LDL-C), and receiving pharmacotherapy. A total of 1 736 032 children were included; 113 780 (6.6%) were screened for dyslipidemia. Screening in 9 to 11 year olds increased from 2009 to 2012. Of children screened, 18 801 (16.5%) had elevated LDL-C; 425 (2.3%) were treated pharmacologically. Parental dyslipidemia, diabetes mellitus, chronic kidney disease, Kawasaki disease, human immunodeficiency virus infection, nephrotic syndrome, liver, thyroid, and other endocrine disorders increased odds of screening. Older age, nephrotic syndrome, chronic kidney disease, diabetes mellitus, and hypertension increased odds of having elevated LDL-C and receiving treatment. Pediatric dyslipidemia screening rates remain low.

References

Mar 1, 1992·American Journal of Public Health·C M Tiwary, A H Holguin
May 1, 1991·American Journal of Epidemiology·L S WebberG S Berenson
Feb 20, 1986·The New England Journal of Medicine·R Ross
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Olli T RaitakariJorma S A Viikari
Nov 16, 2011·Pediatrics·UNKNOWN Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, UNKNOWN National Heart, Lung, and Blood Institute
Dec 17, 2011·JAMA : the Journal of the American Medical Association·Bruce M Psaty, Frederick P Rivara
Jan 19, 2012·JAMA : the Journal of the American Medical Association·Matthew W Gillman, Stephen R Daniels
Aug 16, 2012·The Journal of Clinical Endocrinology and Metabolism·Marianne BennBørge G Nordestgaard
Oct 17, 2012·Current Opinion in Lipidology·Markus JuonalaOlli T Raitakari
Nov 21, 2013·The Journal of Pediatrics·Damon B DixonJulia Steinberger
Feb 27, 2014·JAMA : the Journal of the American Medical Association·Cynthia L OgdenKatherine M Flegal
May 6, 2014·JAMA : the Journal of the American Medical Association·Samuel R VinciSarah D de Ferranti
May 9, 2014·Military Medicine·Patricia A EilermanDavid H Carnahan
Jul 24, 2014·The Cochrane Database of Systematic Reviews·Alpo VuorioEuridiki Drogari
Aug 28, 2014·Circulation. Cardiovascular Quality and Outcomes·Karen L MargolisPatrick J O'Connor
Sep 8, 2015·Journal of Clinical Lipidology·Justin P ZachariahAndrea E Cassidy-Bushrow
Oct 25, 2016·Academic Pediatrics·Anna Jo SmithSanjay Kinra
Nov 24, 2016·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Jonathan Wagner, Susan M Abdel-Rahman
Dec 23, 2016·Clinical Pediatrics·Carole StipelmanNicole L Mihalopoulos
Jan 29, 2017·Clinical Chemistry·Amy B Karger, Amy K Saenger
Feb 18, 2017·The Journal of Pediatrics·Sarah D de FerrantiLaurel K Leslie
Jul 8, 2017·The Cochrane Database of Systematic Reviews·Alpo VuorioUma Ramaswami

❮ Previous
Next ❯

Citations

Feb 27, 2021·Journal of Pediatric Gastroenterology and Nutrition·Rachel Frenklak SivanOrith Waisbourd-Zinman

❮ Previous
Next ❯

Software Mentioned

Stata Intercooled

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.